It is plausible that downregulation of CYP3A activity may cause lower oxycodone dose requirements in those with cancer cachexia, and although this has not been studied, confirming this in a clinical setting may help clinicians toward cautious dosing of oxycodone in patients with cancer cachexia. The gene discussed is CYP3A4; the disease is cancer.